Financial Results - Standalone (Quarter ended June 30, 2026)
- Total Income: ₹6.30 crores (Q1 FY27) vs ₹5.02 crores (Q4 FY26) vs ₹8.79 crores (Q1 FY26)
- Revenue from Operations: ₹1.94 crores
- Other Income: ₹4.36 crores
- Total Expenses: ₹3.65 crores
- Profit before tax and exceptional items: ₹2.65 crores
- Exceptional items: (₹1.74) crores (related to warrant forfeiture)
- Profit before tax: ₹0.91 crores
- Tax expense: (₹0.13) crores (deferred tax)
- Net Profit for the period: ₹1.04 crores
- Total Comprehensive Income: ₹1.02 crores
- Basic EPS: ₹0.44
- Diluted EPS: ₹0.44
Financial Results - Consolidated (Quarter ended June 30, 2026)
- Total Income: ₹227.61 crores
- Revenue from Operations: ₹225.86 crores
- Other Income: ₹1.75 crores
- Total Expenses: ₹211.03 crores
- Profit before tax and exceptional items: ₹16.58 crores
- Exceptional items: (₹1.74) crores
- Profit before tax: ₹14.84 crores
- Tax expense: (₹0.13) crores
- Net Profit for the period: ₹14.97 crores
- Profit attributable to owners: ₹12.70 crores
- Total Comprehensive Income attributable to owners: ₹11.98 crores
- Basic EPS: ₹5.39
- Diluted EPS: ₹5.39
Key Financial Notes
1. The Company has one reportable segment: "Pharma Packaging Research Solutions"
2. Accounts prepared on going-concern basis based on positive GCS business prospects
3. Transferred ₹2.93 crores to IEPF on 10th July 2026 as per NCLT order dated 5th June 2026
4. Asset held for sale with book value of ₹64.07 crores (land parcels)
5. Contingent liability: Penal interest of ₹18.55 crores on CSIR loan (matter subjudice)
6. During quarter: Paid ₹25.58 crores for 75% of 17,05,000 outstanding warrants; 3,15,000 warrants lapsed and ₹1.58 crores forfeited
7. SFIO investigation ongoing since MCA order dated 3 June 2020
Board Approvals
A. Changes in Directors
- Appointment of Mr. Mohan Bhandari (DIN: 00052777) as Executive Director effective 13 August 2026, subject to shareholder approval. Term: 5 years. Shareholding: 5,856,489 equity shares (24.87%). He is promoter, founder and CEO of the company.
- Reappointment of Ms. Kavita Bhansali as Executive Director for further 5 years effective 15 August 2026, subject to shareholder approval. Shareholding: Nil.
B. Changes in Key Managerial Personnel
- Mr. Sagar R. Baheti resigned as Company Secretary, Compliance Officer and KMP on 13 August 2026, effective 24 September 2026 (personal reasons).
- Mr. Mayur Dave appointed as Company Secretary, Compliance Officer and KMP effective 25 September 2026.
C. Subsidiary Update
- Voluntary winding up of Bilcare INC (wholly owned US subsidiary) approved. The subsidiary had nil turnover in FY 2025-26 and is not material.
Auditor's Review
Patki and Soman Chartered Accountants issued limited review reports for both standalone and consolidated results, drawing attention to:
- Going concern assumption based on management's positive outlook for GCS business
- IEPF transfer of ₹2.93 crores completed
- Assets held for sale classification
- Contingent liability for penal interest on CSIR loan
- Warrant conversion and forfeiture transactions
- SFIO investigation status
Board Meeting Details
- Date: 13 August 2026
- Time: 4:30 PM to 8:30 PM (IST)